腺苷酸激酶2抗體
規(guī)格：1mg/1ml
英文名： Adenylate kinase 2
別名： mitochondrial; Adenylate kinase 2; Adenylate kinase isoenzyme 2; ADK2; AK 2; ak2; ATP AMP transphosphorylase; ATP AMP transphosphorylase; ATP-AMP transphosphorylase 2; EC 2.7.4.3; KAD2_HUMAN.
分子量： 26kDa
儲(chǔ)存液：0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glyce
克隆類型：Polyclonal
亞型：IgG
純化方法：affinity purified by Protein A
**原：KLH conjugated synthetic peptide derived from human Adenylat
交叉反應(yīng)：Human, Mouse, Rat, Dog, Pig, Cow, Sheep,
腺苷酸激酶2抗體細(xì)胞定位：細(xì)胞漿 細(xì)胞膜 線粒體
產(chǎn)品介紹：background: Adenylate kinases are involved in regulating the adenine nucleotide composition within a cell by catalyzing the reversible transfer of phosphate groups among adenine nucleotides. Three isozymes of adenylate kinase, namely 1, 2, and 3, have been identified in vertebrates; this gene encodes isozyme 2. Expression of these isozymes is tissue-specific and developmentally regulated. Isozyme 2 is localized in the mitochondrial intermembrane space and may play a role in apoptosis. Mutations in this gene are the cause of reticular dysgenesis. Alternate splicing results in multiple transcript variants. Pseudogenes of this gene are found on chromosomes 1 and 2.[provided by RefSeq, Nov 2010] Function: Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. This small ubiquitous enzyme involved in energy metabolism and nucleotide synthesis that is essential for maintenance and cell growth. Plays a key role in hematopoiesis. Subunit: Monomer. Subcellular Location: Mitochondrion intermembrane space. Tissue Specificity: Present in most tissues. Present at high level in heart, liver and kidney, and at low level in brain, skeletal muscle and skin. Present in thrombocytes but not in erythrocytes, which lack mitochondria. Present in all nucleated cell populations from blood, while AK1 is mostly absent. In spleen and lymph nodes, mononuclear cells lack AK1, whereas AK2 is readily detectable.腺苷酸激酶2抗體 These results indicate that leukocytes may be susceptible to defects caused by the lack of AK2, as they do not express AK1 in sufficient amounts to compensate for the AK2 functional deficits (at protein level). DISEASE: Defects in AK2 are the cause of reticular dysgenesis (RDYS) [MIM:267500]; also known as aleukocytosis. RDYS is the most severe form of inborn severe combined immunodeficiencies (SCID) and is characterized by absence of granulocytes and almost complete deficiency of lymphocytes in peripheral blood, hypoplasia of the thymus and secondary lymphoid organs, and lack of innate and adaptive humoral and cellular immune functions, leading to fatal septicemia within days after birth. In bone marrow of individuals with reticular dysgenesis, myeloid differentiation is blocked at the promyelocytic stage, whereas erythro- and megakaryocytic maturation腺苷酸激酶2抗體 is generally normal.In addition, affected newborns have bilateral sensorineural deafness. Defects may be due to its absence in leukocytes and inner ear, in which its absence can not be compensated by AK1. Similarity: Belongs to the adenylate kinase family. AK2 subfamily. Gene ID: 204 Database links: Entrez Gene: 204 Human Entrez Gene: 11637 Mouse Entrez Gene: 24184 Rat Omim: 103020 Human SwissProt: P54819 Human SwissProt: Q9WTP6 Mouse SwissProt: P29410 Rat Unigene: 470907 Human Unigene: 29460 Mouse Unigene: 3421 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
腺苷酸激酶2抗體產(chǎn)品應(yīng)用：WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
研究領(lǐng)域：細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 線粒體
儲(chǔ)存條件： Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
來源： Rabbit
外觀： Lyophilized or Liquid
- 溫馨提示：為規(guī)避購買風(fēng)險(xiǎn)，建議您在購買前務(wù)必確認(rèn)供應(yīng)商資質(zhì)與產(chǎn)品質(zhì)量。
- 免責(zé)申明：以上內(nèi)容為注冊(cè)會(huì)員自行發(fā)布，若信息的真實(shí)性、合法性存在爭議，平臺(tái)將會(huì)監(jiān)督協(xié)助處理，歡迎舉報(bào)